474 related articles for article (PubMed ID: 16230377)
21. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
22. Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
Chen PH; Peng CY; Pai HC; Teng CM; Chen CC; Yang CR
J Nutr Biochem; 2011 Aug; 22(8):732-40. PubMed ID: 21062671
[TBL] [Abstract][Full Text] [Related]
23. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
24. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
26. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib : a novel therapy for breast cancer?
Scher KS; Somlo G
Expert Opin Investig Drugs; 2013 Jun; 22(6):795-801. PubMed ID: 23594190
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of aqueous extracts of Taraxacum officinale on growth and invasion of breast and prostate cancer cells.
Sigstedt SC; Hooten CJ; Callewaert MC; Jenkins AR; Romero AE; Pullin MJ; Kornienko A; Lowrey TK; Slambrouck SV; Steelant WF
Int J Oncol; 2008 May; 32(5):1085-90. PubMed ID: 18425335
[TBL] [Abstract][Full Text] [Related]
29. The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA.
Fujita H; Kitawaki T; Sato T; Maeda T; Kamihira S; Takaori-Kondo A; Kadowaki N
Eur J Immunol; 2013 Jan; 43(1):93-103. PubMed ID: 23112129
[TBL] [Abstract][Full Text] [Related]
30. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
32. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
33. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3.
Nerreter T; Köchel C; Jesper D; Eichelbrönner I; Putz E; Einsele H; Seggewiss-Bernhardt R
Exp Hematol; 2014 Sep; 42(9):773-82.e1-3. PubMed ID: 24882272
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Chang AY; Wang M
BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
[TBL] [Abstract][Full Text] [Related]
36. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
37. [FAK/c-Src signaling pathway mediates the expression of cell surface HSP90 in cultured human prostate cancer cells and its association with their invasive capability].
Liu XG; Guo Y; Yan ZQ; Guo MY; Zhang ZG; Guo CA
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):340-4. PubMed ID: 21875461
[TBL] [Abstract][Full Text] [Related]
38. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism.
Franzen CA; Amargo E; Todorović V; Desai BV; Huda S; Mirzoeva S; Chiu K; Grzybowski BA; Chew TL; Green KJ; Pelling JC
Cancer Prev Res (Phila); 2009 Sep; 2(9):830-41. PubMed ID: 19737984
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib in solid tumors.
Kim LC; Rix U; Haura EB
Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
